SAN FRANCISCO—Dr Tomasz Beer, said their new data make a good case for using enzalutamide to treat prostate cancer in chemo-naïve patients. He spoke reassuringly about both efficacy and safety.
Tomasz Beer MD, Oregon Health & Science University
“Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study”
ASCO 2014 Genitourinary Cancers Symposium